Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trialPerry B. Shieh, Salvador Rico, Barbara K. Smith et al.|The Lancet Neurology|2023Cited by 120
Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in DogsDavid L. Mack, Martin K. Childers, Karine Poulard et al.|Molecular Therapy|2017Cited by 109
Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species ComparisonsMichael W. Lawlor, Caroline A. Sewry, Alan H. Beggs et al.|Journal of Neuropathology & Experimental Neurology|2016Cited by 66